Seek Returns logo

BMY vs. PHG: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at BMY and PHG, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

BMY is a standard domestic stock, while PHG trades as New York Registered Shares, providing U.S. investors with a way to invest in the foreign-based company.

SymbolBMYPHG
Company NameBristol-Myers Squibb CompanyKoninklijke Philips N.V.
CountryUnited StatesNetherlands
GICS SectorHealth CareHealth Care
GICS IndustryPharmaceuticalsHealth Care Equipment & Supplies
Market Capitalization97.40 billion USD25.94 billion USD
ExchangeNYSENYSE
Listing DateJune 1, 1972March 17, 1980
Security TypeCommon StockNY Reg Shrs

Historical Performance

This chart compares the performance of BMY and PHG by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

BMY vs. PHG: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolBMYPHG
5-Day Price Return5.49%2.43%
13-Week Price Return-0.68%7.53%
26-Week Price Return-16.67%-12.97%
52-Week Price Return1.68%-12.25%
Month-to-Date Return10.48%0.17%
Year-to-Date Return-15.40%-5.16%
10-Day Avg. Volume15.20M1.49M
3-Month Avg. Volume14.69M1.96M
3-Month Volatility30.84%28.75%
Beta0.351.02

Profitability

Return on Equity (TTM)

BMY

29.57%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

In the upper quartile for the Pharmaceuticals industry, BMY’s Return on Equity of 29.57% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

PHG

-0.18%

Health Care Equipment & Supplies Industry

Max
34.53%
Q3
19.38%
Median
9.52%
Q1
4.86%
Min
-7.58%

PHG has a negative Return on Equity of -0.18%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

BMY vs. PHG: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Net Profit Margin (TTM)

BMY

10.59%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

BMY’s Net Profit Margin of 10.59% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.

PHG

0.90%

Health Care Equipment & Supplies Industry

Max
23.34%
Q3
13.06%
Median
9.53%
Q1
5.96%
Min
-3.87%

Falling into the lower quartile for the Health Care Equipment & Supplies industry, PHG’s Net Profit Margin of 0.90% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.

BMY vs. PHG: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Operating Profit Margin (TTM)

BMY

17.82%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

BMY’s Operating Profit Margin of 17.82% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.

PHG

6.11%

Health Care Equipment & Supplies Industry

Max
29.44%
Q3
17.80%
Median
13.95%
Q1
8.73%
Min
-3.56%

PHG’s Operating Profit Margin of 6.11% is in the lower quartile for the Health Care Equipment & Supplies industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.

BMY vs. PHG: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Profitability at a Glance

SymbolBMYPHG
Return on Equity (TTM)29.57%-0.18%
Return on Assets (TTM)5.41%-0.08%
Net Profit Margin (TTM)10.59%0.90%
Operating Profit Margin (TTM)17.82%6.11%
Gross Profit Margin (TTM)73.92%43.85%

Financial Strength

Current Ratio (MRQ)

BMY

1.21

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

BMY’s Current Ratio of 1.21 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

PHG

1.26

Health Care Equipment & Supplies Industry

Max
4.90
Q3
3.05
Median
2.14
Q1
1.49
Min
0.86

PHG’s Current Ratio of 1.26 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

BMY vs. PHG: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Debt-to-Equity Ratio (MRQ)

BMY

2.82

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

With a Debt-to-Equity Ratio of 2.82, BMY operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

PHG

0.81

Health Care Equipment & Supplies Industry

Max
1.49
Q3
0.71
Median
0.45
Q1
0.14
Min
0.00

PHG’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.81. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

BMY vs. PHG: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Interest Coverage Ratio (TTM)

BMY

-4.77

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

BMY has a negative Interest Coverage Ratio of -4.77. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

PHG

1.41

Health Care Equipment & Supplies Industry

Max
58.29
Q3
25.56
Median
9.06
Q1
3.60
Min
-28.92

In the lower quartile for the Health Care Equipment & Supplies industry, PHG’s Interest Coverage Ratio of 1.41 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.

BMY vs. PHG: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Financial Strength at a Glance

SymbolBMYPHG
Current Ratio (MRQ)1.211.26
Quick Ratio (MRQ)1.110.81
Debt-to-Equity Ratio (MRQ)2.820.81
Interest Coverage Ratio (TTM)-4.771.41

Growth

Revenue Growth

BMY vs. PHG: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

BMY vs. PHG: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

BMY

5.14%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

With a Dividend Yield of 5.14%, BMY offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

PHG

0.00%

Health Care Equipment & Supplies Industry

Max
4.05%
Q3
1.76%
Median
0.71%
Q1
0.00%
Min
0.00%

PHG’s Dividend Yield of 0.00% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.

BMY vs. PHG: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Dividend Payout Ratio (TTM)

BMY

98.10%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

BMY’s Dividend Payout Ratio of 98.10% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

PHG

0.42%

Health Care Equipment & Supplies Industry

Max
160.00%
Q3
72.47%
Median
27.49%
Q1
0.00%
Min
0.00%

PHG’s Dividend Payout Ratio of 0.42% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

BMY vs. PHG: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Dividend at a Glance

SymbolBMYPHG
Dividend Yield (TTM)5.14%0.00%
Dividend Payout Ratio (TTM)98.10%0.42%

Valuation

Price-to-Earnings Ratio (TTM)

BMY

19.09

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

BMY’s P/E Ratio of 19.09 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

PHG

137.38

Health Care Equipment & Supplies Industry

Max
73.48
Q3
51.69
Median
34.31
Q1
25.74
Min
11.47

At 137.38, PHG’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Health Care Equipment & Supplies industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

BMY vs. PHG: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Price-to-Sales Ratio (TTM)

BMY

2.02

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

BMY’s P/S Ratio of 2.02 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

PHG

1.24

Health Care Equipment & Supplies Industry

Max
9.53
Q3
5.26
Median
3.39
Q1
2.13
Min
0.00

In the lower quartile for the Health Care Equipment & Supplies industry, PHG’s P/S Ratio of 1.24 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

BMY vs. PHG: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Price-to-Book Ratio (MRQ)

BMY

5.40

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

BMY’s P/B Ratio of 5.40 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

PHG

1.89

Health Care Equipment & Supplies Industry

Max
10.85
Q3
5.98
Median
3.48
Q1
2.43
Min
0.69

PHG’s P/B Ratio of 1.89 is in the lower quartile for the Health Care Equipment & Supplies industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

BMY vs. PHG: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Valuation at a Glance

SymbolBMYPHG
Price-to-Earnings Ratio (TTM)19.09137.38
Price-to-Sales Ratio (TTM)2.021.24
Price-to-Book Ratio (MRQ)5.401.89
Price-to-Free Cash Flow Ratio (TTM)6.6114.38